just now

Liquidity Finder Ltd is incorporated in England and Wales, company number 10610740, registered address 167-169 Great Portland Street, Fifth Floor, London W1W 5PF, United Kingdom.
Published: just now


As healthcare policies evolve, they often spark significant changes in medical markets, public health, and societal expectations. President Joe Biden's recent proposal to broaden Medicare and Medicaid coverage for weight-loss medications is poised to reshape the American healthcare landscape. Here's a look at the potential ripple effects this ambitious plan could create for patients, industries, and the economy.
Biden’s administration seeks to make weight-loss drugs, particularly GLP-1 medications like Ozempic and Wegovy, more accessible to millions of Americans. If implemented in 2026, the plan would cover approximately 7.5 million additional people, including seniors and lower-income households. The initiative could slash out-of-pocket costs by up to 95%, significantly lowering the financial barrier for treatment.
Yet, the future of this proposal lies with the incoming administration. With competing views on government spending and healthcare priorities, the outcome remains uncertain.

Obesity, a long-standing public health challenge, not only burdens individuals but also strains societal resources. The introduction of GLP-1 drugs has already contributed to a slight decline in U.S. obesity rates, particularly among the college-educated demographic with greater access to these treatments. By expanding coverage, the initiative aims to amplify these positive trends.
However, the broader societal cost of obesity encompasses lost productivity and diminished quality of life, factors that drugs alone cannot address. Integrating preventive measures alongside medication will be key to sustainable success.

Expanding access to weight-loss drugs is expected to drive higher demand, benefiting pharmaceutical giants like Eli Lilly and Novo Nordisk. Yet not all sectors will thrive under this shift. For example:
The healthcare sector must brace for these changes, adjusting strategies to meet evolving patient needs and market dynamics.
With demand for GLP-1 drugs set to soar, questions about supply chain readiness come to the forefront. While major manufacturers are investing billions in production facilities, the risk of shortages looms, especially as diabetics continue to rely on these medications. Ensuring equitable distribution will require ongoing coordination among stakeholders.
While the upfront cost of expanded coverage is significant—an estimated $35 billion by 2034—the potential long-term benefits are compelling. Healthier populations could lead to reduced healthcare spending and greater economic productivity. Policymakers and healthcare leaders must weigh these trade-offs to guide decisions that align with both fiscal responsibility and public health goals.
The journey toward broader access to weight-loss medications reflects a broader struggle to balance innovation, accessibility, and equity in healthcare. As policymakers and industries navigate this pivotal moment, the choices they make will influence not just the healthcare landscape, but the well-being of millions.
Sources: ING Think, the winners and losers of Biden’s plans to expand coverage of weight-loss drugs. Published November 28, 2024. Accessed for analysis and interpretation.
This content may have been written by a third party. ACY makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplies by any third-party. This content is information only, and does not constitute financial, investment or other advice on which you can rely.
Why Is Forex Trading So Difficult?
How To Master MT4 & MT5 - Tips And Tricks For Traders
The Importance Of Fundamental Analysis In Forex Trading
Forex Leverage Explained: Mastering Forex Leverage In Trading & Controlling Margin
The Importance Of Liquidity In Forex: A Beginner's Guide
Close All Metatrader Script: Maximise Your Trading Efficiency And Reduce Stress
Best Currency Pairs To Trade In 2024
Forex Trading Hours: Finding The Best Times To Trade FX
MetaTrader Expert Advisor - The Benefits Of Algorithmic Trading And Forex EAs
ACY Securities is one of Australia's fastest growing multi-asset online trading providers, offering ultra-low-cost trading, rock-solid execution, technologically superior account management and premium market analysis.
Select the categories and companies you wish to follow directly to your person rss feed.
Create Custom RSS FeedSign up and join over 5,000 professional members who receive personalized news alerts, curated professional connections, and more for free!
Why did gold keep falling after reaching $3,880? See how a failed 4-hour retest confirmed weakness in XAUUSD and why $3,400 is the next weekly support to watch.
Reality television personality Aaron Chalmers and finfluencer Jason Agbodza have been fined after pleading guilty to illegally promoting an unauthorised foreign exchange trading scheme on social media.
UK retail sales rose a stronger-than-expected 0.7% in October, giving sterling some support, while a deepening tech sell-off pushed the dollar lower overnight against all major currencies. Thanim Islam, Head of FX Analysis at Equals, says the dollar remains in charge as the week ends, with the Fed expected to raise rates more than both the Bank of England and the ECB.
Nvidia beats expectations, reporting $115.8bn in revenue and raising its long-term growth outlook, but the stock still struggled to sustain its gains. AI remains fundamentally strong, but investor expectations are becoming more demanding, particularly around capex and profitability. Wall Street suffered a major sell-off, with the S&P 500 entering a six-session losing streak as rate concerns intensified.
iSAM Securities reviews the ris of weekend gold trading
Webull Corporation reported record third quarter 2026 revenue of $218.7 million, up 39% year-on-year, with customer assets reaching $32.4 billion and options contracts volume up 79%. Net income attributable to the company was $31.2 million, while margin debit balances passed $1 billion for the first time.
Anthropic, the company behind the Claude family of AI models, begins trading on the Nasdaq today under the ticker ANT. It priced its shares at $83 last night, above its marketed range of $70 to $78, and raised about $81.3 billion. That makes it the largest initial public offering on record, ahead of the roughly $75 billion SpaceX raised in June. This note covers what investors need to know: the terms, the business, how the company is governed, and what to watch.
Nvidia's first results without Jensen Huang answered the question that has hung over the AI trade since October. Revenue of $115.8 billion beat consensus by about $7 billion, fourth-quarter guidance of $130 billion came in roughly $5 billion above expectations, and the company raised its outlook for next fiscal year to around 75% growth. All of this assumes no data-centre sales to China.
Marex has entered the football financing market through a partnership with specialist sports investment and advisory firm Pinto Capital, targeting clubs in the Premier League and EFL Championship.
Around 110,000 UK retail investors have secured $300 million worth of Anthropic shares in its record-breaking $81 billion IPO. The heavily oversubscribed offer, coordinated by RetailBook, saw smaller investors prioritised, with 63% of applicants receiving their full allocation.